CN115103677A - Atr抑制剂与parp抑制剂的组合的用途 - Google Patents
Atr抑制剂与parp抑制剂的组合的用途 Download PDFInfo
- Publication number
- CN115103677A CN115103677A CN202080096191.XA CN202080096191A CN115103677A CN 115103677 A CN115103677 A CN 115103677A CN 202080096191 A CN202080096191 A CN 202080096191A CN 115103677 A CN115103677 A CN 115103677A
- Authority
- CN
- China
- Prior art keywords
- optionally substituted
- cancer
- alkyl
- aryl
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962946876P | 2019-12-11 | 2019-12-11 | |
| US62/946876 | 2019-12-11 | ||
| PCT/US2020/064662 WO2021119523A1 (en) | 2019-12-11 | 2020-12-11 | Use of atr inhibitors in combination with parp inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115103677A true CN115103677A (zh) | 2022-09-23 |
Family
ID=76316464
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080096191.XA Pending CN115103677A (zh) | 2019-12-11 | 2020-12-11 | Atr抑制剂与parp抑制剂的组合的用途 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20210177856A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4072551A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023506787A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220128350A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115103677A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020402108A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022011426A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3164203A1 (cg-RX-API-DMAC7.html) |
| CL (1) | CL2022001540A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL293810A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022007163A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021119523A1 (cg-RX-API-DMAC7.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117159725A (zh) * | 2023-04-06 | 2023-12-05 | 上海交通大学医学院附属仁济医院 | 通过dna水凝胶促进小分子药物结晶达到缓释效果的方法 |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210097124A (ko) | 2018-10-30 | 2021-08-06 | 리페어 세라퓨틱스 인크. | 화합물, 약제 조성물, 및 화합물 제조 방법 및 atr 키나제 억제제로서의 이것들의 사용 방법 |
| KR20220035925A (ko) | 2019-07-22 | 2022-03-22 | 리페어 세라퓨틱스 인크. | Atr 키나제 억제제로서의 치환된 2-모르폴리노피리딘 유도체 |
| JP2024522736A (ja) * | 2021-06-16 | 2024-06-21 | リペア セラピューティクス インコーポレイテッド | がん治療のためのparp阻害剤と組み合わせたatr阻害剤の使用 |
| EP4504208A1 (en) * | 2022-04-07 | 2025-02-12 | Repare Therapeutics Inc. | Methods of using atr inhibitors |
| KR20250023494A (ko) * | 2022-06-15 | 2025-02-18 | 아스트라제네카 아베 | 암 치료를 위한 병용 요법 |
| WO2024164089A1 (en) * | 2023-02-09 | 2024-08-15 | Repare Therapeutics Inc. | Use of atr inhibitors in the treatment of cancers with high tumor mutational burden |
| WO2024243078A1 (en) * | 2023-05-19 | 2024-11-28 | Leapfrog Bio, Inc. | Hsp90 inhibitors for the treatment of cancer |
| JP2026518747A (ja) * | 2023-05-23 | 2026-06-09 | ザ フランシス クリック インスティテュート リミテッド | Alt陽性がんの治療のための標的 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060142231A1 (en) * | 2003-12-01 | 2006-06-29 | Alan Ashworth | DNA damage repair inhibitors for treatment of cancer |
| CN106795156A (zh) * | 2014-08-04 | 2017-05-31 | 拜耳制药股份公司 | 2‑(吗啉‑4‑基)‑1,7‑萘啶 |
| WO2018153973A1 (en) * | 2017-02-24 | 2018-08-30 | Bayer Pharma Aktiengesellschaft | Combination of atr kinase inhibitors with parp inhibitors |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210097124A (ko) * | 2018-10-30 | 2021-08-06 | 리페어 세라퓨틱스 인크. | 화합물, 약제 조성물, 및 화합물 제조 방법 및 atr 키나제 억제제로서의 이것들의 사용 방법 |
| KR20220035925A (ko) * | 2019-07-22 | 2022-03-22 | 리페어 세라퓨틱스 인크. | Atr 키나제 억제제로서의 치환된 2-모르폴리노피리딘 유도체 |
-
2020
- 2020-12-11 IL IL293810A patent/IL293810A/en unknown
- 2020-12-11 US US17/119,512 patent/US20210177856A1/en not_active Abandoned
- 2020-12-11 WO PCT/US2020/064662 patent/WO2021119523A1/en not_active Ceased
- 2020-12-11 KR KR1020227023568A patent/KR20220128350A/ko not_active Withdrawn
- 2020-12-11 BR BR112022011426A patent/BR112022011426A2/pt not_active IP Right Cessation
- 2020-12-11 EP EP20898316.3A patent/EP4072551A4/en not_active Withdrawn
- 2020-12-11 JP JP2022535631A patent/JP2023506787A/ja active Pending
- 2020-12-11 CA CA3164203A patent/CA3164203A1/en active Pending
- 2020-12-11 AU AU2020402108A patent/AU2020402108A1/en not_active Abandoned
- 2020-12-11 MX MX2022007163A patent/MX2022007163A/es unknown
- 2020-12-11 CN CN202080096191.XA patent/CN115103677A/zh active Pending
-
2022
- 2022-06-09 CL CL2022001540A patent/CL2022001540A1/es unknown
-
2023
- 2023-12-12 US US18/537,061 patent/US20240350505A1/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060142231A1 (en) * | 2003-12-01 | 2006-06-29 | Alan Ashworth | DNA damage repair inhibitors for treatment of cancer |
| CN106795156A (zh) * | 2014-08-04 | 2017-05-31 | 拜耳制药股份公司 | 2‑(吗啉‑4‑基)‑1,7‑萘啶 |
| WO2018153973A1 (en) * | 2017-02-24 | 2018-08-30 | Bayer Pharma Aktiengesellschaft | Combination of atr kinase inhibitors with parp inhibitors |
Non-Patent Citations (1)
| Title |
|---|
| HYOUNG KIM,ET AL.: "Targeting the ATR/CHK1 axis with PARP inhibition results in tumor regression in BRCA mutant models", 《CLIN CANCER RES.》, vol. 23, no. 12, pages 3097 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117159725A (zh) * | 2023-04-06 | 2023-12-05 | 上海交通大学医学院附属仁济医院 | 通过dna水凝胶促进小分子药物结晶达到缓释效果的方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| BR112022011426A2 (pt) | 2022-08-30 |
| JP2023506787A (ja) | 2023-02-20 |
| KR20220128350A (ko) | 2022-09-20 |
| MX2022007163A (es) | 2022-08-25 |
| EP4072551A1 (en) | 2022-10-19 |
| IL293810A (en) | 2022-08-01 |
| WO2021119523A8 (en) | 2021-08-05 |
| EP4072551A4 (en) | 2023-11-15 |
| AU2020402108A1 (en) | 2022-07-14 |
| US20240350505A1 (en) | 2024-10-24 |
| US20210177856A1 (en) | 2021-06-17 |
| WO2021119523A1 (en) | 2021-06-17 |
| CA3164203A1 (en) | 2021-06-17 |
| CL2022001540A1 (es) | 2023-01-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023506787A (ja) | Parp阻害薬と組み合わせたatr阻害薬の使用 | |
| JP2024522736A (ja) | がん治療のためのparp阻害剤と組み合わせたatr阻害剤の使用 | |
| ES2885003T3 (es) | Estimuladores de SGC fusionados bicíclicos | |
| JP6867295B2 (ja) | 置換2,3−ジヒドロイミダゾ[1,2−c]キナゾリンを含んでいる組合せ | |
| TW202400178A (zh) | 使用atr抑制劑之方法 | |
| BR112021006033A2 (pt) | Uso de um inibidor de um transportador da família ent no tratamento de câncer e combinação do mesmo com um antagonista do receptor de adenosina | |
| KR20080096657A (ko) | 인지 장애의 치료 방법 | |
| CA2730428A1 (en) | Methods for regulating cell mitosis by inhibiting serine/threonine phosphatase | |
| BR112019005337A2 (pt) | terapia combinada | |
| HK1250645A1 (zh) | 取代的2,3-二氢咪唑并[1,2-c]喹唑啉类化合物的用途 | |
| JPH02121935A (ja) | 大脳卒中の治療のための薬剤 | |
| CN104023715A (zh) | 激酶抑制剂的副作用降低剂 | |
| WO2020062951A1 (zh) | 化合物及其用途 | |
| ES2749433T3 (es) | Apremilast para el tratamiento de una enfermedad hepática o una anomalía de la función hepática | |
| HK40079144A (en) | Use of atr inhibitors in combination with parp inhibitors | |
| JP4232866B2 (ja) | 細胞障害抑制剤 | |
| WO2024164089A1 (en) | Use of atr inhibitors in the treatment of cancers with high tumor mutational burden | |
| EP4656193A1 (en) | Pharmaceutical composition for treating tumors | |
| JP5154408B2 (ja) | 好酸球増加症候群のためのピリミジルアミノベンズアミド誘導体 | |
| HK40107484A (en) | Use of atr inhibitors in combination with parp inhibitors for treating cancer | |
| EP2685983A1 (en) | Novel use of imidazotriazinones | |
| WO2022216930A1 (en) | Novel mda-9 antagonist with anti-metastatic potential | |
| ES2341517A1 (es) | Utilizacion de un compuesto inhibidor de la activacion de la enzima erk 1/2 en el tratamiento de enfermedades neurodegenerativas. | |
| WO2025181153A1 (en) | Use of atr inhibitors in combination with pi3k alpha inhibitors | |
| CN102884067A (zh) | 内耳障碍的预防或治疗药 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40079144 Country of ref document: HK |
|
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20220923 |
|
| WD01 | Invention patent application deemed withdrawn after publication |